Home World News Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA... World News Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 822 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Similar Efficacy Between Subcutaneous and Intravenous Pembrolizumab Given with Chemotherapy for... April 14, 2025 Alcohol linked to more than 740,000 new cancer cases globally in... July 14, 2021 Oxaliplatin-Based Adjuvant Chemotherapy Shows Good Tolerance and Similar Time To Recurrence... April 4, 2024 ΣΤΑΤΙΣΤΙΚΑ January 18, 2019 Load more HOT NEWS Seven Centres to form new Cancer Research UK network Breast Cancer Survivor Given 12 Months to Live After Left Side... El cáncer en mi comunidad: Superar los retrasos en la atención... Happy 29th Birthday OncoLink!
